San Francisco, CA, United States of America

Lawrence Hamann

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Interdict Bio, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lawrence Hamann. Retrieved from https://idiyas.com/inventor/lawrence-hamann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lawrence Hamann and Small-Molecule Protein Synthesis Modulators.

Introduction

Lawrence Hamann is an inventor based in San Francisco, California, and is associated with Interdict Bio, Inc. His work includes a patent application concerning compounds designed to modulate protein synthesis.

Latest Patents

Hamann is credited with 1 patent. His patent, “Small Molecule Protein Synthesis Modulators,” describes compounds and their pharmaceutically acceptable salts for modulating protein synthesis. It also covers pharmaceutical compositions and kits containing these compounds, as well as methods for treating or preventing diseases and disorders associated with targets such as BCL-2, MYC, CCND1, MCL-1, ALK, and KRAS-G12D.

Career Highlights

Hamann’s listed work is connected to Interdict Bio, Inc., a company focused on biotechnology. The patent disclosure reflects an approach to therapeutic research that seeks to influence protein synthesis and address diseases associated with specific molecular targets.

Collaborations

His listed coworkers include Sogole Sami Bahmanyar and Zef Konst. Their shared association with the company provides context for Hamann’s professional network.

Conclusion

Lawrence Hamann’s patent work at Interdict Bio, Inc. centers on small-molecule approaches to modulating protein synthesis, with potential applications in treating or preventing diseases linked to several molecular targets.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…